Skip to main content

Table 2 Mean cyst burden per mouse brain 4 weeks after challenge with 20 cysts of Toxoplamsa gondii strain PRU per mouse

From: Protective efficacy of Toxoplasma gondiicalcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice

Group (n = 3) No. of brain cysts (Means ± S.D.) % reduction*
Control 3117 ± 140A** -
PBS 3067 ± 125A 1.6
PVAX I 3067 ± 125A 1.6
pVAX-CDPK1 1758 ± 150B 45.7
pVAX-IL-21-IL-15 1692 ± 111B 43.6
pVAX-CDPK1 + pVAX-IL-21-IL-15 850 ± 104C 72.7
  1. *The reduction of brain cysts were from the values for the blank control group.
  2. **The same superscript letter means no statistically significant difference (P > 0.05) between different experimental groups, whereas different superscript letters mean statistically significant difference among different experimental groups from the same measurement (P < 0.05).
  3. A The superscript letter A means no statistically significant difference (P > 0.05) between the groups of pVAX I, PBS and control.
  4. B The superscript letter B means no statistically significant difference (P > 0.05) between the groups of pVAX-CDPK1 and pVAX-IL-21-IL-15, but it means significant differences of the No. of brain cysts in these two groups in contrast to the control group.
  5. C The superscript letter C means significant differences of the No. of brain cysts in the group of pVAX-IL-21-IL-15 + pVAX-CDPK1 in contrast to the groups of pVAX-CDPK1 and pVAX-IL-21-IL-15 (P < 0.05).